Faculty of Pharmacy, National and Kapodistrian University of Athens, Laboratory of Biopharmaceutics-Pharmacokinetics, Panepistimiopolis, 15771, Athens, Greece.
Expert Opin Drug Metab Toxicol. 2011 Jan;7(1):79-88. doi: 10.1517/17425255.2011.539202. Epub 2010 Dec 1.
The ultimate goal of bioequivalence is to assess the expected in vivo equivalence of two drug products of the same active moiety.
In this review, we present the classic approach of bioequivalence assessment, some situations of special importance such as the role of metabolites and highly variable drugs, and the current regulatory state in North America and Europe. Special emphasis is given to the methods proposed for solving the problems caused by high variability such as multiple-dose studies, replicate designs, individual bioequivalence and the widening of bioequivalence limits. Other issues discussed include the concept of biowaivers and the rising field of the equivalence of biologicals (biosimilars).
The reader will gain an understanding of why bioequivalence assessment is necessary, how it is performed and what one should be aware of when planning to conduct a bioequivalence study.
The aim of bioequivalence studies is to ensure comparable in vivo performance of two drug products. This is accomplished by performing an appropriate clinical study which should be capable of ensuring the drug's safety and efficacy for consumers with less human exposure and costs of producing.
生物等效性的最终目标是评估两种相同活性成分药物产品的预期体内等效性。
在本篇综述中,我们介绍了生物等效性评估的经典方法,以及一些特别重要的情况,如代谢物和高变异药物的作用,以及北美和欧洲目前的监管状况。特别强调了为解决高变异性引起的问题而提出的方法,如多剂量研究、重复设计、个体生物等效性和放宽生物等效性限度。其他讨论的问题包括生物豁免的概念和生物类似物(biosimilars)这一新兴领域。
读者将了解为什么需要进行生物等效性评估,如何进行评估,以及在计划进行生物等效性研究时应注意哪些问题。
生物等效性研究的目的是确保两种药物产品具有可比较的体内性能。这是通过进行适当的临床研究来实现的,该研究应能够确保药物对消费者的安全性和疗效,同时减少人体暴露和生产成本。